New American Kidney Fund Education Campaign Highlights Connection Between Kidney Disease and Gout
August 21, 2018 10:05 ET
|
American Kidney Fund
ROCKVILLE, Md., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Aiming to demystify gout, an extremely painful form of inflammatory arthritis, the American Kidney Fund (AKF) today unveiled a new health education...
National Gout Awareness Day: American Kidney Fund Highlights Connection Between Gout and Kidney Disease
May 22, 2018 11:15 ET
|
American Kidney Fund
ROCKVILLE, Md., May 22, 2018 (GLOBE NEWSWIRE) -- Tuesday, May 22, is National Gout Awareness Day and the American Kidney Fund (AKF) is joining a nationwide effort to educate people about the...
Horizon Pharma plc Launches GoutRevealed.com to Spotlight the Journey and Stories of People Living with Uncontrolled Gout
May 22, 2018 09:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, May 22, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today marked Gout Awareness Day with the launch of Gout Revealed, which was created to spotlight real-life stories...
Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
November 07, 2017 07:30 ET
|
Selecta Biosciences, Inc.
Patient Data From Ongoing Phase 2 Trial to be Presented Today at the American College of Rheumatology (ACR) 2017 Annual MeetingPreparations for Phase 3 Program UnderwayReceived $7.5 Million From Spark...
Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
November 06, 2017 12:00 ET
|
Horizon Pharma plc
-- Initial data from investigator-initiated TRIPLE study shows infusion reactions occurred in less than 1 percent of infusions -- -- Analyses further support the efficacy and safety of KRYSTEXXA -- ...
Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
November 03, 2017 11:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc to Present KRYSTEXXA® (pegloticase injection) Data for the Management of Uncontrolled Gout at the 2017 ACR/ARHP Annual Meeting
October 23, 2017 08:00 ET
|
Horizon Pharma plc
-- Initial data from investigator-initiated TRIPLE study to be presented on Nov. 6 -- -- Horizon Pharma plc to host an investor call on Nov. 9 following the ACR/AHRP Annual Meeting -- DUBLIN,...
Selecta Biosciences Reports Data from Ongoing Phase 2 Trial of Lead Candidate, SEL-212, in Development for Chronic Severe Gout
June 15, 2017 07:30 ET
|
Selecta Biosciences
WATERTOWN, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
Horizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled Gout
June 14, 2017 09:05 ET
|
Horizon Pharma plc
DUBLIN, Ireland, June 14, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993
June 14, 2017 09:00 ET
|
Horizon Pharma plc
MADRID, Spain, June 14, 2017 (GLOBE NEWSWIRE) -- Results from a new study to be presented tomorrow at the Annual European Congress of Rheumatology (EULAR) 2017 show a 410 percent increase in...